CAD/POLD2 gene expression is associated with poor overall survival and chemoresistance in bladder urothelial carcinoma
Givechian KB, Garner C, Garban H, Rabizadeh S, Soon-Shiong P. CAD/POLD2 gene expression is associated with poor overall survival and chemoresistance in bladder urothelial carcinoma. Oncotarget 2018, 9: 29743-29752. PMID: 30038717, PMCID: PMC6049856, DOI: 10.18632/oncotarget.25701.Peer-Reviewed Original ResearchBladder urothelial carcinomaPoor overall survivalUrothelial carcinomaOverall survivalBladder urothelial carcinoma patientsUrothelial carcinoma patientsPlatinum-based therapyMechanisms of chemoresistancePatient tumor samplesRepair genesSystemic chemotherapyFavorable survivalNucleotide excision repair genesWorse survivalCarcinoma patientsPoor survivalTherapeutic strategiesTherapy resistancePyrimidine synthesis pathwayRepair processClinical targetsTumor samplesPatientsCarcinomaDNA repair genes